RxDoctor Payments Data

Thomas Hoffmann, MD

MOHS-Micrographic Surgery · Apple Valley, CANPI 1306885140

Payments from drug & device makers

$384in general payments, 2019–2025

Across 9 payments — averaging $42.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$172
  • Johnson & Johnson$58
  • UCB, Inc.$58
  • Regeneron Healthcare Solutions, Inc.$40
  • Revance Therapeutics, Inc.$32
  • Paratek Pharmaceuticals, Inc.$24

What the payments were for

  • Food & beverage$384100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$384 in reported general payments places this provider in the 15th percentile of 144 mohs-micrographic surgery providers in California.

See all mohs-micrographic surgery providers in California

Medicare billing

Part B allowed, 2024
$1,299,347
Medicare patients
717
Services billed
14,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole12$17,812
Fluticasone Propionate85$2,121
Metronidazole33$2,077
Desonide12$1,614
Clobetasol EmollientClobetasol Propionate/Emoll27$1,502
Fluorouracil14$1,410
Clobetasol Propionate22$1,180
Sulfacetamide Sodium11$1,042
Ketoconazole70$1,039
Clindamycin Phosphate29$1,034
Mupirocin96$948
Triamcinolone Acetonide43$704
Cephalexin90$513
Econazole Nitrate22$464
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$432

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$172$17,81212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 144 mohs-micrographic surgery providers in California.

Other mohs-micrographic surgery in Apple Valley

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →